The Evolving Role of Rituximab in Adult Minimal Change Glomerulopathy | Zendy

Landon C. Brown | Zendy; Meghan A. Jobson | Zendy; Fernanda Payan Schober | Zendy; Emily Chang | Zendy; Ronald J. Falk | Zendy; Patrick H. Nachman | Zendy; William F. Pendergraft | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Evolving Role of Rituximab in Adult Minimal Change Glomerulopathy

Author(s) -

Landon C. Brown,

Meghan A. Jobson,

Fernanda Payan Schober,

Emily Chang,

Ronald J. Falk,

Patrick H. Nachman,

William F. Pendergraft

Publication year - 2017

Publication title -

american journal of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.394

H-Index - 85

eISSN - 1421-9670

pISSN - 0250-8095

DOI - 10.1159/000464475

Subject(s) - medicine , rituximab , glomerulopathy , immunology , glomerulonephritis , antibody , kidney

Minimal-change glomerulopathy is defined histologically by the presence of normal glomeruli on light microscopy and diffuse podocyte effacement on electron microscopy. Although effective in children, corticosteroid treatment in adults is more variable and time to response can be prolonged. Data to support rituximab use in adults with corticosteroid-dependent or resistant minimal-change glomerulopathy are limited. Here, we describe the clinical course of adults with corticosteroid-dependent or -resistant minimal-change glomerulopathy who received rituximab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research